Skip to main content

Table 3 Prognostic factors for progression-free survival

From: FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study

 

N (%)

Univariate analysis

Multivariable analysis

P-value

hazard ratio

95% CIe

P-value

Age: >  70 (vs. ≤ 70)

19 (44)

0.454

   

Sex: female (vs. male)

13 (30)

0.447

   

ECOG PSa: 1–2 (vs. 0)

32 (74)

0.189

1.450

0.523–4.026

0.475

Disease status: recurrence (vs. metastatic)

9 (21)

0.222

   

Treatment line: 4th or later (vs. 3rd)

9 (21)

0.112

0.503

0.205–1.239

0.135

CEAb(ng/mL): >  10.0 (vs. ≤ 10.0)

23 (53)

0.012

1.958

0.845–4.537

0.117

CA 19–9c (U/mL): >  2000 (vs. ≤ 2000)

24 (56)

0.122

0.434

0.651–2.720

0.434

Albumin (g/dL): ≤ 3.5 (vs. >  3.5)

24 (56)

0.663

   

CRPd (mg/dL): >  1.0 (vs. ≤ 1.0)

16 (37)

0.021

2.037

1.010–4.107

0.047

  1. a ECOG PS Eastern Cooperative Oncology Group performance status
  2. b CEA Carcinoembryonic antigen
  3. c CA 19–9 Carbohydrate antigen 19–9
  4. d CRP C-reactive protein
  5. e CI Confidence interval